Watch: The long-term care crisis: Why few can afford to grow old in America

The FDA has released revised draft guidance on communicating with healthcare professionals (HCPs) about unapproved uses of approved drugs and devices. Once it’s finalized, the

PHILADELPHIA — A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial.

A chemotherapy-free regimen combining the investigational therapy eftilagimod alpha with pembrolizumab (Keytruda) showed promising efficacy in a small cohort of patients with recurrent or metastatic